Depomed and Madaus have announced that the marketing authorization application (MAA) for their ProQuin XR was accepted for review by the Medical Products Agency in Sweden. Madaus submitted the MAA earlier this year, seeking approval for ProQuin XR for the treatment of uncomplicated urinary tract infections (UTIs). ProQuin XR is a once-daily, prolonged release formulation of ciprofloxacin hydrochloride, which was developed by Depomed.
UTIs are bacterial infections frequently caused by E. coli and are typically treated with antibiotics. ProQuin XR is generally well-tolerated. The most common side-effects with ProQuin XR include vaginal yeast infection and headache. ProQuin XR is commercially available in the U.S. through Esprit Pharma.